Salt Lake City, UT, United States
Salt Lake City, UT, United States

Time filter

Source Type

Platform Now Covers Over One Million Lives Across Several Dozen Large Employers SALT LAKE CITY, UT--(Marketwired - May 09, 2017) - Artemis Health, a health data analytics company, raised $8.3 million in Series A funding to empower employers with needed transparency and insights into their benefits data in order to provide better benefits to its workforce. Maverick Ventures, a leading funder of health technology startups such as Castlight Health, Collective Health and One Medical Group, led the financing in late 2016. "Data is at the heart of business decision making, but employers struggle to access actionable, up-to-date data on what they spend on employee healthcare," said Grant Gordon, CEO of Artemis Health. "We've been busy putting this funding to work to grow our incredible team, reach more clients, make the Artemis Platform more powerful, and ensure that our customers can easily capture the value in their data. We're well-positioned to lead the complex work of reducing healthcare costs for employers and employees." For most large, self-insured employers, approximately 30 percent of their healthcare dollars could be considered waste. These employers have traditionally turned to data warehouses to run complex, time-consuming and hard-to-understand reports. Artemis Health solves this problem and gives employers insight into their spending. The Artemis platform helps self-insured employers identify overspending and gaps in care, find solutions, and measure results to ensure that their employees get the best possible care at the best possible price. Artemis Health launched in 2013 when founders Grant Gordon, Dallin Regehr and Dallen Allred saw a need for employer-facing data analytics software in a user-friendly package. The funding round also added board member Ashok Subramanian, former co-founder and CEO of Liazon and the head of the Group Exchange business at Willis Towers Watson, to the Artemis Health team. "We invested in Artemis because it gives benefit managers and brokers an elegant, easy-to-use platform that helps them identify areas of overspending, quickly take action, and evaluate the potential of future benefits offerings," said Ambar Bhattacharyya, Managing Director at Maverick Ventures, who has also recently joined the Artemis Board of Directors. "Benefit managers are inundated with choice, and Artemis allows them to determine the ROI of the programs that are actually working. The reaction has been overwhelming; the customer satisfaction is off the charts." Artemis Health now serves over 20 large employers with more than a million covered employees. Artemis Health helps companies utilize their data to optimize their benefits programs while minimizing their spend. The Artemis Platform provides customers with actionable data on their benefits programs, opportunities and gaps, and easy-to-use tools to help them make great decisions. By making it easy for self-insured employers to use their own benefits data, our mission is to help fix healthcare in America and ensure access to good healthcare everyone can afford. Based in Salt Lake City, Artemis Health works with dozens of employers nationwide including Intuit, GE Appliances and AAA. Discover more at www.artemishealth.com. Maverick Capital is a global investment firm that has been investing in early stage companies for over 20 years. By working with Maverick Ventures, entrepreneurs get the best of both worlds -- a focused, agile team of venture partners -- and the resources, reputation and relationships of a multi-billion dollar fund. Maverick Ventures invests through an evergreen structure that allows it to support entrepreneurs for an indefinite time horizon. Learn more about Maverick Ventures at http://www.maverickventures.com/.


Patent
Artemis Health | Date: 2011-01-24

Methods and kits for selectively enriching non-random polynucleotide sequences are provided. Methods and kits for generating libraries of sequences are provided. Methods of using selectively enriched non-random polynucleotide sequences for detection of fetal aneuploidy are provided.


Patent
Artemis Health | Date: 2010-03-31

The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions.


The present invention relates to methods comprising whole genome sequencing for identifying polymorphisms in samples comprising mixtures of genomes, and for determining and/or monitoring the presence or absence of disorders associated with the identified polymorphisms.


The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample.


Patent
Artemis Health | Date: 2010-03-31

The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions.


The present invention provides a method capable of detecting single or multiple fetal chromosomal aneuploidies in a maternal sample comprising fetal and maternal nucleic acids, and verifying that the correct determination has been made. The method is applicable to determining copy number variations (CNV) of any sequence of interest in samples comprising mixtures of genomic nucleic acids derived from two different genomes, and which are known or are suspected to differ in the amount of one or more sequence of interest. The method is applicable at least to the practice of noninvasive prenatal diagnostics, and to the diagnosis and monitoring of conditions associated with a difference in sequence representation in healthy versus diseased individuals.


Patent
Artemis Health | Date: 2010-07-30

Fragile cells have value for use in diagnosing many types of conditions. There is a need for compositions that stabilize fragile cells. The stabilization compositions of the provided invention allow for the stabilization, enrichment, and analysis of fragile cells, including fetal cells, circulating tumor cells, and stem cells.


Patent
Artemis Health | Date: 2011-01-19

Methods are disclosed for resolving measurement problems such problems in measuring chromosomal copy number. Some disclosed methods involve first selecting a primary assay element characteristic to partition. Such characteristic may be a source of experimental variability such as the GC content of measured DNA sequences. Additionally, the disclosed methods may employ an abundance or copy number function to transform the assay element frequencies into an abundance, dose, copy number score, or the like. In some cases, the disclosed methods estimate an amount of certain fetal DNA in a sample. The methods can further compare the estimated amount to a measured amount of fetal DNA in the sample. The comparison can be used to determine the fetal sex or aneuploidy.


The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample.

Loading Artemis Health collaborators
Loading Artemis Health collaborators